747 844
Genomic Research at NorthShore University HealthSystem in support of
Dr. Jianfeng Xu
[31_TD$DIFF]
.
[32_TD$DIFF]
We acknowledge Mr. Bob Aikens, Peter Bing, Warren
Schwerin, and Frank Strang for their generous support
[33_TD$DIFF]
of
[34_TD$DIFF]
Dr. William
Isaacs.
We also acknowledge Dr. Shan Zha for helpful discussions. We would
thank John & Carol Walter family and Donald & Joan Rappeprt family for
their support. Finally we thank all the patients for their participation in
this study.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2016.11.033.
References
[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA Cancer J Clin 2015;65:87–108.[2]
Al Olama AA, Kote-Jarai Z, Berndt SI, et al. A meta-analysis of 87 040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014;46:1103–9.
[3]
Szulkin R, Karlsson R, Whitington T, et al. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Bio- markers Prev 2015;24:1796–800.[4]
Xu J, Sun J, Zheng SL. Prostate cancer risk-associated genetic markers and their potential clinical utility. Asian J Androl 2013; 15:314–22.
[5]
Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med (Berl) 1997;75: 758–61.
[6]
Johannsson O, Loman N, Mo¨ller T, Kristoffersson U, Borg A, Olsson H. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999;35:1248–57.[7]
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310–6.
[8]
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2 : a review of the literature. J Clin Oncol 2004;22:735–42.
[9]
Hart SN, EllingsonMS, Schahl K, et al. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 2016;6: e010332.
[10]
Akbari MR, Wallis CJD, Toi A, et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J Cancer 2014;111:1238–40.[11]
Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localized prostate cancer. Eur Urol 2015;68:186–93.
[12]
Castro E, Goh C, Olmos D, Saunders E, et al. Germline BRCA muta- tions are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748–57.
[13]
Edwards SM, Evans DGR, Hope Q, et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010;103:918–24.[14]
Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010;16:2115–21.
[15]
Maier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate 2014; 74:1444–51.
[16]
Mitra a, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502–7.
[17]
Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008;99:371–4.[18]
Tryggvado´ ttir L, Vidarsdo´ ttir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929–35.
[19]
Risbridger GP, Taylor RA, Clouston D, et al. Patient-derived xeno- grafts reveal that intraductal carcinoma of the prostate is a promi- nent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 2015;67:496–503.[20]
Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011;105:1230–4.[21]
Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1–12.[22]
Agalliu I, Kwon EM, Zadory D, et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007;13:839–43.
[23]
Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 2000;60:1371–5.
[24]
Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215–28.
[25]
Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443–53.[26]
Li H, Durbin R. Fast and accurate short read alignment with Bur- rows-Wheeler transform. Bioinformatics 2009;25:1754–60.
[27]
Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21:577–81.[28]
Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42:D980–5.[29]
Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565–74.[30]
Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, featured updates to the NCCN Guidelines, Version 2.2016. J Natl Compr Cancer Netw 2016;14:509–19.[31]
Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10: 2918–21.
[32]
Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401–8.E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 4 0 – 7 4 7
747